Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

1.

AGO Austria recommendations for genetic testing of patients with ovarian cancer.

Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.

Wien Klin Wochenschr. 2015 Jun 25. [Epub ahead of print]

PMID:
26109557
2.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.

PMID:
26017449
3.

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.

Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.

Cancer Lett. 2015 Jul 1;362(2):218-28. doi: 10.1016/j.canlet.2015.03.040. Epub 2015 Apr 8.

4.

Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer.

Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, King MC, Lajus TB.

Hered Cancer Clin Pract. 2015 Jan 16;13(1):2. doi: 10.1186/s13053-014-0022-x. eCollection 2015.

5.

Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.

Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE.

Am J Surg Pathol. 2015 Mar;39(3):287-93. doi: 10.1097/PAS.0000000000000369.

PMID:
25581732
6.

The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.

Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Holter S, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, Foulkes WD, Gilks CB, Clarke BA.

Am J Surg Pathol. 2014 Sep;38(9):1173-81. doi: 10.1097/PAS.0000000000000298.

PMID:
25025451
7.
8.

Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.

Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK.

Ann Surg Oncol. 2014 Oct;21(11):3466-72. doi: 10.1245/s10434-014-3747-x. Epub 2014 May 6.

PMID:
24796968
9.

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.

Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).

Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.

PMID:
24789418
10.

Risk factors for ovarian cancers with and without microsatellite instability.

Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J.

Int J Gynecol Cancer. 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134.

PMID:
24755492
11.

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.

Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S.

PLoS One. 2014 Apr 18;9(4):e95649. doi: 10.1371/journal.pone.0095649. eCollection 2014.

12.

BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.

Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H.

Cancer. 2014 Jul 1;120(13):1960-7. doi: 10.1002/cncr.28662. Epub 2014 Apr 15.

13.

Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.

Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M.

Jpn J Clin Oncol. 2014 Jun;44(6):597-601. doi: 10.1093/jjco/hyu035. Epub 2014 Apr 9.

14.

Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.

Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.

Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.

PMID:
24681744
15.

Better therapeutic trials in ovarian cancer.

Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.

J Natl Cancer Inst. 2014 Apr;106(4):dju029. doi: 10.1093/jnci/dju029. Epub 2014 Mar 13. Review.

16.

Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.

Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.

Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.

17.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.

Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.

18.

Hereditary ovarian and breast cancer: what have we learned?

Lynch HT, Snyder C, Casey MJ.

Ann Oncol. 2013 Nov;24 Suppl 8:viii83-viii95. doi: 10.1093/annonc/mdt313. Review.

19.

Alternatives to risk-reducing surgery for ovarian cancer.

Gadducci A, Sergiampietri C, Tana R.

Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311. Review.

20.

Coming into focus: the nonovarian origins of ovarian cancer.

Dubeau L, Drapkin R.

Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35. doi: 10.1093/annonc/mdt308. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk